Similar Posts
MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]
So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.
Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.
Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer StudyRemember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestorLinks to Clinical trials :
https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkYhttps://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
Psychedelic Spotlight Interview with Rabbi Zac Kamenetz
In this episode of the Psychedelic Spotlight podcast, we speak…
A Club DJ’s Advice on Building Better Psychedelic Playlists
Psychedelic playlists should minimize lyrics, focus on building an emotional arc, and other helpful tips to improve your trips.
Journaling for Psychedelic Integration with Jenalle Dion, Wakeful Travel
Jenalle talks with Spotlight about the cultivation of her journal company, Wakeful Travel, and her story of pivoting from a travel-focus to the integration space.
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
Interview With Chris Kilham, Medicine Hunter Inc.
Chris works alongside companies to develop plant-based food and medicinal products, helping turn them into market successes. He has conducted medicinal plant research and sustainable botanical sourcing in over 45 countries, and has been featured on a number of platforms such as The New York Times, The Dr. Oz Show, Business Insider, CNN, VICE, and much more.